Skip to NavigationSkip to content

News

Array BioPharma has announced that it has pulled its new drug application (NDA) for its drug, binimetinib, for the treatment of NRAS-mutant melanoma...
Genentech, Roche’s biotech group, has announced its plans to conduct a second Phase 3 study for crenezumab, its anti-Abeta antibody for the...
It can currently take up to three or four years for a new drug to reach market in China, slowing patient access to the latest medication. It also...
Pakistan is facing an increasing problem with people suffering from diabetes. At a recent conference, the 4th International Diabetes Conference, it...
Pulmocide has secured $30.4 million in Series B financing to further develop two wholly-owned treatments for respiratory syncytial virus (RSV) and...
An unsettling new investigation has revealed a potential cover-up of birth defects linked to a hormone pregnancy test, with echoes of the thalidomide...
From Trump's FDA pick to some alarming findings on common painkiller ibuprofen, check out a round up of the most read, shared and discussed topics...
Dana M. Krueger and Neha Rajdev, of Russell Reynolds, discuss the importance of a scientific background in the boardrooms of the pharmaceutical...
The FDA has issued Badrivishal Chemicals & Pharmaceuticals a warning letter regarding numerous violations of manufacturing codes. The most...
A Tokyo court has ruled ex-Novartis employee Nobuo Shirahashi not guilty of violating a pharmaceutical affairs law against deceitful drug...